A step from Covid-19 pills as Merck & Co seeks FDA approval


and its partner Ridgeback Biotherapeutics LP sought emergency use authorization in the U. S. for molnupiravir, moving the pill closer to becoming the first oral antiviral treatment for Covid-19. An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization, the companies said in a statement Monday. Submissions to regulatory authorities worldwide are expected in the coming months after interim analysis of clinical trial data found that it cut the risk of hospitalization for such patients by half. “The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data,” said Robert M. Davis, Merck’s chief executive officer and president. “We look forward to working with the FDA on its review of our application, and to working with other regulatory agencies as we do everything we can to bring molnupiravir to patients around the world as quickly as possible.” Molnupiravir can be given to patients at home, unlike Gilead Sciences Inc.’s antiviral remdesivir and monoclonal antibody therapies, which are administered via an intravenous infusion usually in a hospital or a clinic. Treating Covid-19 patients at home avoids the risk of them transmitting the virus to medical staff and other patients. Merck shares traded 1% lower in pre-market trading at 6:35 a.m. in New York, erasing part of an earlier decline. A five-day course of molnupiravir will cost about $700 per patient — a third of the amount of a monoclonal antibody treatment, according to the New York Times. Safe, well-tolerated, affordable and easy-to-administer antivirals are ideal treatments because they directly counter the virus, limiting its damage to the body and the duration of illness. Steroids and blood-thinners that have been shown to improve survival in hospitalized patients don’t directly fight the virus; rather they prevent a worsening of Covid symptoms. Merck reiterated that it expects to make 10 million treatment courses by the end of 2021, with more doses slated for production in 2022.

The drugmaker agreed in June to a $1.2 billion supply deal with the U. S. government under which it will provide 1.7 million courses of the treatment once the drug gains emergency use authorization or approval from the FDA.

antibody cocktail clears study to treat virus

AstraZeneca’s experimental Covid-19 drug has helped cut the risk of severe disease or death in a late-stage study, the British drugmaker said on Monday, a boost to its efforts to develop medicines beyond vaccines. The drug, a cocktail of two antibodies called AZD7442, reduced the risk of severe COVID-19 or death by 50 per cent in non-hospitalised patients who have had symptoms for seven days or less. AstraZeneca’s therapy, delivered via injection, is the first of its kind to show promise both as a preventative medicine and as a treatment for Covid-19 following multiple trials. It is designed to protect people who do not have a strong enough immune response to vaccines. “These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic,” Hugh Montgomery, the trial’s principal investigator, said. Similar therapies made with a class of drugs called monoclonal antibodies are being developed. The trial took place across 13 countries and involved more than 900 adult participants, said. (Reuters)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *